Abstract
Background: It was demonstrated that the novel metabolic agent, trimetazidine, could lessen the incidence and severity of angina, whether used in monotherapy or combination. Although the animal studies demonstrated that trimetazidine reduces myocardial infarct size and improves recovery of mechanic function after ischemia, little is known on the potential benefits of trimetazidine in patients with acute myocardial infarction (AMI). The aim of this study was to evaluate the efficacy of trimetazidine on AMI by sub-maximal exercise test.
Methods: A double-blind crossover trimetazidine versus placebo trial was carried out in 44 patients with AMI. Patients were randomly allotted into trimetazidine (23 patients) or placebo (21 patients) for 5 days and underwent an initial sub-maximal exercise test. Exercise tests according to the modified Bruce protocol were performed. Exercise end points included completion of stage II or 75% of maximum predicted heart rate whichever came first. An averaged 12-lead ECG was obtained at rest, every minute during exercise, at the onset of anginal symptoms, at the onset of 1-mm ST segment depression, at peak exercise and every 2-minute during recovery. After the initial exercise tests, study groups resumed the drugs in the opposite order for 4 to 5 days and underwent a second sub-maximal exercise test.
Results: Exercise induced ST segment depression was noted in 17 patients (38.6%) receiving placebo. However, exercise induced ST-segment depression was observed in 8 patients (18.1%) taking TMZ. Positive exercise test results were significantly higher in placebo group than TMZ group (p = 0.018). Additionally, trimetazidine prolonged the time to 1-mm ST-segment depression (6.1 ± 0.5 vs 4.9 ± 0.4, p < 0.031) and exercise duration (7.2 ± 0.9 vs 5.8 ± 0.9, p < 0.025).
Conclusion: Trimetazidine therapy improves the exercise capacity and reduces evidence of ischemia derived from sub-maximal post-infarction exercise testing.
References
Detry JM,Sellier P,Pennaforte S,Cokkinos D,Dargie H,Mathes P. Trimetazidine: A new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 1994; 37: 279-288.
Michaelides AP,Spiropoulos K,Dimopoulos K,Athanasiades D,Toutouzas P. Antianginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina. Clin Drug Invest 1997; 13: 8-14.
Levy S, and the Group of South of France Investigators. Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Am J Cardiol 1995; 76: 12B-16B.
Lu C,Dabrowski P,Fragasso G,Chierchia SL. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998; 82: 898-901.
Dalla Volta S,Maraglino G,della Valentina P,Viena P,Desideri A. Comparison of trimetazidine with nifedipine in effort angina: A double-blind crossover study. Cardiovasc Drugs Ther 1990; 4: 853-860.
Drake-Holland AJ,Belcher PR,Hynd J,Noble MI. Infarct size in rabbits: A modified method illustrated by the effects of propranolol and trimetazidine. Basic Res Cardiol 1993; 88: 250-258.
Noble MI,Belcher PR,Drake-Holland AJ. Limitation of infarct size by trimetazidine in the rabbit. Am J Cardiol 1995; 76(6): 41B-44B.
The EMIP-FR Group. Effect of 48-h intravenous trimetazidine on short-and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy. Eur Heart J 2000; 21: 1537-1546.
Kantor PF,Lucien A,Kozak R,Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain-3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580-588.
Williams FM,Tanda K,Kus M,William TJ. Trimetazidine inhibits neutrophil accumulation after myocardial ischemia and reperfusion in rabbits. J Cardiovasc Pharmacol 1993; 22: 828-833.
Lavanchy N,Martin J,Rossi A. Anti-ischemic effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 1987; 286: 97-110.
Manchanda SC,Krishnaswami S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 1997; 78: 353-357.
Passeron J. Efficacy of trimetazidine in stable effort angina. Double-blind study against placebo. Presse Med 1986; 15: 1775-1778.
Goupit P. Pharmococine'tique de la trimetazidine. Concours Med 1987; 36 (Suppl): 3447-3451.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Güler, N., Eryonucu, B., Güneş, A. et al. Effects of Trimetazidine on Submaximal Exercise Test in Patients with Acute Myocardial Infarction. Cardiovasc Drugs Ther 17, 371–374 (2003). https://doi.org/10.1023/A:1027376529708
Issue Date:
DOI: https://doi.org/10.1023/A:1027376529708